In this study, we found more active glucose metabolism of CD4+ Tregs than CD4+ Teffs in peripheral blood of patients with OC and that of patients with benign ovarian tumor (BOT) and healthy control (HC), suggesting that it may have a better effect on tumor immunotherapy with CD4+ Tregs as target cells. This evidence concerns the gene CD4 and ovarian benign neoplasm.